

Sheet 1 of 2

Substitute Form PTO-1449 (Modified) <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-407US1	Application No. 10/517,800
	Applicant Esteban Celis		
	Filing Date December 13, 2004	Group Art Unit	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
SH	AA	5,662,907	09/02/1997	Kubo et al.			
SH	AB	5,869,453	02/09/1999	Moss et al.			
SH	AC	6,162,440	12/19/2000	Hayward et al.			
	AD						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
SH	AE	WO95/24925	09/21/1995	WIPO				
	AF							
	AG							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
SH	AH	Babcock et al., "EBV Persistence in Memory B Cells In Vivo", Immunity, 1998, 9:395-404
SH	AI	Cristiano et al., "Molecular conjugates: a targeted gene delivery vector for molecular medicine", J. Mol. Med., 1995, 73:479-486
SH	AJ	Di Tommaso et al., "Induction of Antigen-Specific Antibodies in Vaginal Secretions by Using a Nontoxic Mutant of Heat-Labile Enterotoxin as a Mucosal Adjuvant", Infect. Immunity, 1996, 64:974-979
SH	AK	Finberg, "Epstein-Barr virus-specific T cells for the management of Epstein-Barr virus lymphomas", Current Opinion Oncology, 2001, 13:349-353
SH	AL	Hopwood et al., "The role of EBV in post-transplant malignancies: a review", J. Clin. Pathol., 2000, 53:248-254
SH	AM	Hsieh et al., "The biology of Epstein-Barr virus in post-transplant lymphoproliferative disease", Transpl. Infect. Dis., 1999, 1:204-212
SH	AN	Khanna et al., "Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease", Proc. Natl. Acad. Sci. USA, 1999, 96(18):10391-10396
SH	AO	Khanna et al., "Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing", Int. Immunol., 1997, 9(10):1537-1543
SH	AP	Khanna et al., "Class I Processing-Defective Burkitt's Lymphoma Cells Are Recognized Efficiently by CD4 <sup>+</sup> EBV-Specific CTLs", J. Immunol., 1997, 158(8):3619-3625
SH	AQ	Kieff, "Epstein-Barr Virus and Its Replication" Fields Virology, 1996, Fields, Knipe, and Howley, eds. Lipincott-Raven Publishers, New York, pp.2343-2396

Examiner Signature <i>Sharon Hunt</i>	Date Considered <i>Sept 24, 2007</i>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-407US1	Application No. 10/517,800
	Applicant Esteban Celis		
	Filing Date December 13, 2004	Group Art Unit	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
SH	AR	Kobayashi et al., "Tumor-reactive T Helper Lymphocytes Recognize a Promiscuous MAGE-A3 Epitope Presented by Various Major Histocompatibility Complex Class II Alleles", Cancer Res., 2001, 61:4773-4778
SH	AS	Kobayashi et al., "Defining Promiscuous MHC Class II Helper T-Cell Epitopes for the HER2/neu Tumor Antigen", Cancer Res., 2000, 60:5228-5236
SH	AT	Lu et al., "Use of Two Predictive Algorithms of the World Wide Web for the Identification of Tumor-reactive T-Cell Epitopes", Cancer Res., 2000, 60:5223-5227
SH	AU	Marsh, "Nomenclature for Factors of the HLA System, Update March 2002", Human Immunol., 2002, 63:515-516
SH	AV	Nalesnik, "Clinical and pathological features of post-transplant lymphoproliferative disorders (PTLD)", Springer Semin. Immunopathol., 1998, 20:325-342
SH	AW	Nikiforow et al., "CD4 <sup>+</sup> T-Cell Effectors Inhibit Epstein-Barr Virus-Induced B-Cell Proliferation", J. Virol., 2001, 75(8):3740-3752
SH	AX	Paya et al., "Epstein-Barr Virus-Induced Posttransplant Lymphoproliferative Disorders", Transplantation, 1999, 68(10):1517-1525
SH	AY	Penix et al., "Two Essential Regulatory Elements in the Human Interferon $\gamma$ Promoter Confer Activation Specific Expression in T Cells", J. Experim. Med., 1993, 178:1483-1496
SH	AZ	Rickinson et al., "Human Cytotoxic T Lymphocyte Responses to Epstein-Barr Virus Infection", Ann. Rev. Immunol., 1997, 15:405-31
SH	AAA	Rowe, "Epstein-Barr Virus Immortalization and Latency", Front. Biosci., 1999, 4:D346-371
SH	ABB	Sigal et al., "Cyclosporin A, FK-506, and Rapamycin: Pharmacologic Probes of Lymphocyte Signal Transduction", Annu. Rev. Immunol., 1992, 10:510-560
SH	ACC	Southwood et al., "Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires", J. Immunol., 1998, 160:3363-3373
SH	ADD	Thomson et al., "Targeting a Polyepitope Protein Incorporating Multiple Class II-Restricted Viral Epitopes to the Secretory/Endocytic Pathway Facilitates Immune Recognition by CD4 <sup>+</sup> Cytotoxic T Lymphocytes: a Novel Approach to Vaccine Design", J. Virol., 1998, 72(3):2246-2252
SH	AEE	Thompson et al., "cis-Acting Sequences Required for Inducible Interleukin-2 Enhancer Function Bind a Novel Ets-Related Protein, Elf-1", Mol. And Cell. Biol., 1992, 12(3):1043-1053
SH	AFF	Todd et al., "Transcription of the Interleukin 4 Gene Is Regulated by Multiple Promoter Elements", J. Exp. Med., 1993, 177:1663-1674
SH	AGG	Yamamoto et al., "Mutants in the ADP-ribosyltransferase Cleft of Cholera Toxin Lack Diarrheagenicity by Retain Adjuvanticity", J. Exp. Med., 1997, 185(7):1203-1210

Examiner Signature <i>Sharon Hunt</i>	Date Considered <i>Sept. 24, 2007</i>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	